Targeting receptor tyrosine kinases in gastric cancer

doi:10.3748/wjg.v20.i16.4536

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 16

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11801)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

785

WORD

364

HTML

6817

Figures (1-1)

598

Tables (1-1)

468

Sum=9032

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1276

Download

1493

Sum=2769

Apr 28, 2014 (publication date) through Nov 8, 2025

Times Cited of This Article

Times Cited (47)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Topic Highlight

World J Gastroenterol. Apr 28, 2014; 20(16): 4536-4545
Published online Apr 28, 2014. doi: 10.3748/wjg.v20.i16.4536

Table 1 Phase III trials of targeted Receptor tyrosine kinases in advenced gastric cancer

Clinical trial	Line of treatment	RTK inhibitor	Chemotherapy	Status
ToGA	First	Trastuzumab	FP or XP	Completed
AVAGAST	First	Bevacizumab	XP	Completed
EXPAND	First	Cetuximab	XP	Completed
REAL-3	First	Panitumumab	EOX	Completed
LoGIG	First	Lapatinib	OX	Ongoing
TYTAN	Second	Lapatinib	T	Ongoing

ToGA: Trastuzumab for gastric cancer; AVAGAST: Avastin in gastric cancer; EXPAND: Erbitux in combination with xeloda and cisplatin in advanced esophago-gastric cancer; REAL-3: Randomized ECF for advanced and locally advanced esophagogastric cancer 3; LoGIG: Lapatinib optimization study in ErbB2 (HER-2) positive gastric cancer; TYTAN: Lapatinib (Tykerb) with paclitaxel (Taxol) in Asian ErbB2+ (HER+) gastric cancer study; F: 5-fluorouracil; P: Cisplatin; X: Capecitabine; E: Epirubicin; T: Paclitaxel.

Full Size Table

Citation: Morishita A, Gong J, Masaki T. Targeting receptor tyrosine kinases in gastric cancer. World J Gastroenterol 2014; 20(16): 4536-4545
URL: https://www.wjgnet.com/1007-9327/full/v20/i16/4536.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i16.4536